Literature DB >> 28316538

Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Syed I M Thiwan1, Douglas A Drossman1.   

Abstract

Functional gastrointestinal disorders (FGIDs) are complex in their physiology and clinical presentation. With no known biologic marker, investigators and clinicians use the Rome criteria to make a positive diagnosis. Psychosocial factors, although not part of these criteria, do contribute to illness presentation, severity, healthcare-seeking behavior and response to treatment. In this regard, psychoactive drugs are valuable in the management of FGIDs, particularly for patients with severe symptoms. The appropriate selection of antidepressants based on predominant symptom, side-effect profile, and psychological condition is an integral part of a successful management program.

Entities:  

Keywords:  antidepressants; central effects; functional gastrointestinal disorders; psychoactive drugs; visceral analgesic effects

Year:  2006        PMID: 28316538      PMCID: PMC5350580     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  67 in total

1.  Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study.

Authors:  Dominic H Lam; Paul McCrone; Kim Wright; Natalie Kerr
Journal:  Br J Psychiatry       Date:  2005-06       Impact factor: 9.319

2.  Effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake, on morphine analgesia and the development of tolerance.

Authors:  A A Larson; A E Takemori
Journal:  Life Sci       Date:  1977-12-15       Impact factor: 5.037

Review 3.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

4.  Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.

Authors:  R E Kast
Journal:  Support Care Cancer       Date:  2001-09       Impact factor: 3.603

5.  Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans.

Authors:  A B Gorelick; S S Koshy; F G Hooper; T C Bennett; W D Chey; W L Hasler
Journal:  Am J Physiol       Date:  1998-09

6.  Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.

Authors:  Smriti Iyengar; Amy A Webster; Susan K Hemrick-Luecke; Jimmy Yu Xu; Rosa Maria A Simmons
Journal:  J Pharmacol Exp Ther       Date:  2004-07-13       Impact factor: 4.030

7.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

8.  Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.

Authors:  D A Gorard; G W Libby; M J Farthing
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

9.  Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial.

Authors:  Gary Tabas; Mary Beaves; Jiping Wang; Paul Friday; Houssam Mardini; George Arnold
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

10.  Buspirone inhibits corticotropin-releasing factor and stress-induced cecal motor response in rats by acting through 5-HT1A receptors.

Authors:  J A Martinez; L Buéno
Journal:  Eur J Pharmacol       Date:  1991-09-24       Impact factor: 4.432

View more
  2 in total

1.  Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders.

Authors:  Madhusudan Grover; Spencer D Dorn; Stephan R Weinland; Christine B Dalton; Bradley N Gaynes; Douglas A Drossman
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

2.  Factors related to irritable bowel syndrome and differences among subtypes: A cross-sectional study in the UK Biobank.

Authors:  Kexin Wang; Huan Liu; Jingjing Liu; Liyuan Han; Zheng Kang; Libo Liang; Shengchao Jiang; Nan Meng; Peiwen Chen; Qiao Xu; Qunhong Wu; Yanhua Hao
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.